15th February 2008, Sydney, Australia: Medical Therapies Limited (ASX: MTY), today announced that it has completed its ‘first-in-human’ clinical trial of Cuprindo™ to determine its safety, tolerability and systemic absorption characteristics. The Phase 1 trial was conducted using a topical suppository formulation in preparation for a planned efficacy study in proctitis patients.

Interim results from patient diaries indicate that Cuprindo™ is safe and well tolerated. The trial subjects, healthy volunteers, reported 100% compliance with the dosing protocol which involved application of Cuprindo™ suppositories twice daily over a seven day period. In addition, post-trial colonoscopy on the subjects uncovered healthy mucosa and no evidence of rectal inflammation or ulceration.

While the trial was not geared to assess Cuprindo™’s systemic efficacy one subject reported relief in chronic joint pain after Day 4 of the trial. Results of the full biochemical analysis of the trial assays, including information on systemic absorption characteristics of Cuprindo™, are expected in the coming weeks.

“The trial has been a success confirming our pre-clinical safety information on Cuprindo™ and it paves the way for our efficacy study in patients with proctitis,” said Dr Stephanie Williams, Chief Scientific Officer of MTY.

Proctitis is a debilitating disease characterised by inflammation and ulceration of the colon, resulting in tiny open sores that can bleed and produce mucus. Symptoms of the disease include chronic diarrhea, bloody stools and, in severe cases, fecal incontinence.

Current treatments such as corticosteroids and immuno-modulators can cause serious side effects and provide no relief for up to 30% of proctitis patients. A topically applied safe treatment, such as a Cuprindo™ suppository, could provide a much needed alternative for the 1 in 60 people suffering from the disease.
About Medical Therapies Limited (ASX: MTY):
Medical Therapies Limited is an Australian pharmaceutical development company committed to the commercialisation of its drug candidates for cancer and anti-inflammatory conditions including cholecystitis, and distal proctitis. The Company’s patent-protected technologies include a number of metal complexes of anti-inflammatory drugs showing increased safety and reduced toxicity in pre-clinical trials. Medical Therapies has also been active is seeking complementary technologies to its existing anti-cancer and anti-inflammatory portfolio.

Investment in biotechnology companies
There are a number of inherent risks associated with the research, development and commercialisation of pharmaceutical products. Investment in companies specialising in these activities carry specific risks which are different to those associated with trading and manufacturing businesses. As such, these companies should be regarded as highly speculative. Medical Therapies recommends that investors seek professional advice before making an investment in its shares.

Forward-looking statement
This Announcement may contain forward looking statements regarding the Company’s business and commercialisation objectives. These statements should be viewed as “at risk” and they are subject to the technical and commercial risks associated with companies engaged in developing pharmaceutical products. Although Medical Therapies may not publish changes to forward looking statements it will release all material information to the market in a timely manner.